1. Bone marrow adiposity during pathologic bone loss: molecular mechanisms underlying the cellular events
- Author
-
Jiao Li, Yi Liu, Lingyun Lu, and Xijie Yu
- Subjects
RNA, Untranslated ,Stromal cell ,Osteoporosis ,Osteoclasts ,Adipose tissue ,Epigenesis, Genetic ,chemistry.chemical_compound ,Bone Marrow ,Adipocyte ,Drug Discovery ,Adipocytes ,Animals ,Humans ,Medicine ,Bone Resorption ,Genetics (clinical) ,Adiposity ,Adipogenesis ,business.industry ,Mesenchymal Stem Cells ,Osteoblast ,medicine.disease ,Molecular medicine ,Haematopoiesis ,medicine.anatomical_structure ,chemistry ,Cancer research ,Molecular Medicine ,Bone marrow ,business - Abstract
Bone marrow (BM) is a heterogeneous niche where bone marrow stromal cells (BMSCs), osteoblasts, osteoclasts, adipocytes, hematopoietic cells, and immune cells coexist. The cellular composition of BM changes with various pathophysiological states. A reduction in osteoblast number and a concomitant increase in adipocyte number in aging and pathological conditions put bone marrow adipose tissue (BMAT) into spotlight. Accumulating evidence strongly supports that an overwhelming production of BMAT is a major contributor to bone loss disorders. Therefore, BMAT-targeted therapy can be an efficient and feasible intervention for osteoporosis. However, compared to blocking bone-destroying molecules produced by BMAT, suppressing BMAT formation is theoretically a more effective and fundamental approach in treating osteoporotic bone diseases. Thus, a deep insight into the molecular basis underlying increased BM adiposity during pathologic bone loss is critical to formulate strategies for therapeutically manipulating BMAT. In this review, we comprehensively summarize the molecular mechanisms involved in adipocyte differentiation of BMSCs as well as the interaction between bone marrow adipocytes and osteoclasts. More importantly, we further discuss the potential clinical implications of therapeutically targeting the upstream of BMAT formation in bone loss diseases.
- Published
- 2021